Category Archive for: ‘ISTO’

FDA Approval to Initiate a Clinical Trial for a Novel Treatment for Disc Nucleus Regeneration

Apr 28, 2009 08:00 ETISTO Technologies ST. LOUIS, MO–(Marketwire – April 28, 2009) – ISTO Technologies, Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) allowing the company to proceed with a Phase I clinical study for NuQu™, a cell-based injectable formulation of juvenile chondrocytes designed to regenerate cartilage, restore disc function and …

Read More